References
- Frankel S R, Eardley A, Lauwers G, Weiss M, Warrell R P, Jr. The ‘retinoic acid syndrome’ in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292–296
- Park C J, Bae Y D, Choi J Y, Heo P S, Lee K S, Park Y S, et al. Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid. Korean J Intern Med 2001; 16: 218–221
- Akiyama H, Nakamura N, Nagasaka S, Sakamaki H, Onozawa Y. Hypercalcemia due to all-trans retinoic acid. Lancet 1992; 339: 308–309
- Nagasawa M, Okawa H. All-trans retinoic acid induced hypercalcemia in a patient with acute promyelocytic leukemia: its relation to increased PTH-rP. Int J Hematol 1994; 59: 143–144
- Niesvizky R, Siegel D S, Busquets X, Nichols G, Muindi J, Warrell R P, Jr., Michaeli J. Hypercalcemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma. Br J Haematol 1995; 89: 217–218
- Sakakibara M, Ichikawa M, Amano Y, Matsuzawa S, Agematsu K, Mori T, et al. Hypercalcemia associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Leuk Res 1993; 17: 441–443
- Choo-Kang E. A review of the aetiology and pathogenesis of hypercalcemia. West Indian Med J 1984; 33: 213–219
- Lemez P. Hypercalcemia cause by all-trans retinoic acid (ATRA) treatment in a case of acute promyelocytic leukaemia was manageable after decreasing the ATRA dose to 27 mg/m2/day. Eur J Haematol 1995; 55: 275–276
- Sakamoto O, Yoshinari M, Rikiishi T, Fujiwara I, Imaizumi M, Tsuchiya S, et al. Hypercalcemia due to all-trans retinoic acid therapy for acute promyelocytic leukemia: a case report of effective treatment with bisphosphonate. Pediatr Int 2001; 43: 688–690
- Suzumiya J, Asahara F, Katakami H, Kimuran N, Hisano S, Okumura M, et al. Hypercalcemia caused by all-trans retinoic acid treatment of acute promyelocytic leukaemia: case report. Eur J Haematol 1994; 53: 126–127
- Valentic J P, Elias A N, Weinstein G D. Hypercalcemia associated with oral isotretinoin in the treatment of severe acne. JAMA 1983; 250: 1899–1900
- Miles A MV, Markell M S, Sumrani N, Hong J, Friedman E A. Severe hyperparathyroidism associated with prolonged hungry bone syndrome in a renal transplant recipient. J Am Soc Nephrol 1997; 8: 1626–1631
- Marill J, Cresteil T, Lanotte M, Chabot G. Identification of human cytochrome P450s involved in the formation of all-trans-retionic acid principle metabolites. Mol Pharmacol 2000; 58: 1341–1348
- Vanier K L, Mattiussi A J, Johnston D L. Interaction of all-trans-retinoic acid with fluconazole in acute promyelocytic leukemia. J Pediatr Hematol Oncol 2003; 25: 403–404
- Rigas J R, Francis P A, Muindi J R, Kris M G, Huselton C, DeGrazia F, et al. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 1993; 85: 1921–1926
- Hyland R, Jones B C, Smith D A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metabol Dispos 2003; 31: 540–547
- Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrobial Agents Chemother 2002; 46: 3091–3093
- VFEND™. Product Monograph. , et al. Pfizer Inc., Quebec August, 2004
- Vesanoid™. Product Monograph. , et al. Roche Laboratories Inc., Nutley, NJ October, 2004